This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...
Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...
Daily Maverick on MSN7h
Efficacy of six-monthly HIV prevention jab confirmed in second major studyIn June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...
Failure to ensure that everyone has access to prevention options to protect oneself from HIV acquisition, has resulted in at ...
The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...
In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.
Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback